Cerus (NASDAQ:CERS) Shares Down 5.5% – Should You Sell?

Posted by Brian Himes on Jun 30th, 2026

Cerus Corporation (NASDAQ:CERS – Get Free Report)’s stock price dropped 5.5% during mid-day trading on Tuesday . The stock traded as low as $2.84 and last traded at $2.8250. 103,616 shares were traded during trading, a decline of 95% from the average session volume of 2,079,274 shares. The stock had previously closed at $2.99.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Cerus in a report on Thursday, June 18th. Zacks Research upgraded shares of Cerus from a “strong sell” rating to a “hold” rating in a report on Thursday, April 30th. BTIG Research raised shares of Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Friday, May 1st. Finally, Wall Street Zen raised shares of Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $4.00.

View Our Latest Analysis on Cerus

Cerus Trading Down 6.2%

The stock has a 50-day moving average of $2.53 and a 200 day moving average of $2.27. The company has a quick ratio of 1.06, a current ratio of 1.63 and a debt-to-equity ratio of 0.47. The stock has a market cap of $562.04 million, a PE ratio of -56.10 and a beta of 1.76.

Cerus (NASDAQ:CERS – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.02. The business had revenue of $59.89 million during the quarter, compared to analysts’ expectations of $55.68 million. Cerus had a negative net margin of 4.41% and a negative return on equity of 15.18%. As a group, sell-side analysts anticipate that Cerus Corporation will post -0.02 earnings per share for the current year.

Insider Buying and Selling at Cerus

In other Cerus news, Director Eric Bjerkholt sold 20,454 shares of Cerus stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $2.60, for a total transaction of $53,180.40. Following the completion of the transaction, the director owned 261,679 shares in the company, valued at approximately $680,365.40. This trade represents a 7.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Vivek K. Jayaraman sold 16,667 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $3.00, for a total value of $50,001.00. Following the completion of the transaction, the chief operating officer directly owned 1,656,707 shares of the company’s stock, valued at approximately $4,970,121. This trade represents a 1.00% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 53,788 shares of company stock valued at $153,182. 3.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Cerus

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cibc World Markets Corp acquired a new position in Cerus in the fourth quarter valued at approximately $25,000. MML Investors Services LLC purchased a new stake in Cerus during the fourth quarter worth $37,000. Caitong International Asset Management Co. Ltd boosted its holdings in Cerus by 68.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 18,712 shares of the biotechnology company’s stock worth $39,000 after buying an additional 7,603 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Cerus during the first quarter valued at $35,000. Finally, Bingham Private Wealth LLC acquired a new stake in Cerus during the fourth quarter valued at $40,000. 78.37% of the stock is owned by institutional investors and hedge funds.

About Cerus

(Get Free Report)

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.